Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Side effects === Injection site reactions are common. More rarely, patients can experience joint swelling, joint pain, carpal tunnel syndrome, and an increased risk of diabetes. In some cases, the patient can produce an immune response against GH. GH may also be a risk factor for Hodgkin's lymphoma. One survey of adults that had been treated with replacement cadaver GH (which has not been used anywhere in the world since 1985) during childhood showed a mildly increased incidence of colon cancer and prostate cancer, but linkage with the GH treatment was not established.
=== Bufotenin === Bufotenin is found in the skin and glands of toads belonging to the genus Bufo. It is commonly used in the Caribbean and China. In the Caribbean, it is used as an aphrodisiac called 'Love Stone'; in China, it is used as a heart medication called Chan su. Research shows that the toad skin secretion containing this compound can reduce a toad’s heart rate, but its effect on humans is unknown.
=== Body wall === The body wall layers include a thin cuticle covering, an epidermis consisting of a single layer of cells, a thick dermis formed of connective tissue, a thin coelomic myoepithelial layer for the muscles, and a peritoneum which lines the body cavity. The dermis contains an endoskeleton of calcium carbonate components known as ossicles. These are honeycomb-like structures composed of calcite microcrystals arranged in a lattice. They vary in form, from flat plates to granules to spines, and cover the aboral (top) surface. Some are specialised structures such as the madreporite (the entrance to the water vascular system), pedicellariae, and paxillae. Paxillae are umbrella-like structures found on starfish that live buried in substrate. The edges of adjacent paxillae meet to form a false cuticle with a water cavity beneath in which the madreporite and delicate gill structures are protected. The ossicles are located under the epidermal layer, even those emerging externally. Several groups of starfish, including Valvatida and Forcipulatida, possess pedicellariae. These are scissor-like ossicles at the tip of the spine which displace organisms from resting on the starfish's surface. Some species like Labidiaster annulatus and Novodinia antillensis use their pedicellariae to catch prey. There may also be papulae, thin-walled protrusions of the body cavity that reach through the body wall into the surrounding water. These serve a respiratory function.
Sources: en.wikipedia.org
=== Mechanism of action === Fialuridine (FIAU) is thymidine-like nucleoside analogue that was investigated as an antiviral against hepatitis B virus (HBV). HBV replication depends on its viral polymerase, which acts as reverse transcriptase and makes viral DNA. Because FIAU-TP resembles the normal nucleotide TTP, the viral polymerase can use FIAU-TP as an alternative substrate during DNA synthesis. This disrupts replication in two related ways. Fist, FIAU-TP can directly inhibit hepatitis virus DNA polymerase activity (shown in the duck hepatitis B virus model). Second, FIAU-TP interferes with the early protein-priming stage of reverse transcription. In an in-vitro priming system, FIAU-TP caused premature termination of the short starter DNA, which prevents proper extension into full-length viral DNA. Importantly, FIAU is not a classic obligate chain terminator, because it still has an intact 3’-OH group. However, once FIAU is incorporated into the growing DNA strand, extension becomes strongly slowed or blocked after a short step, so it behaves as a ‘de facto’ chain terminator. So FIAU's antiviral action can be summarized as follows: after FIAU is converted inside the cell into the active triphosphate form FIAU-TP, it can be used by the viral polymerase during BHV reverse transcription. This interaction disrupts the priming step and subsequent DNA chain synthesis, which eventually reduces the formation of complete viral DNA genomes.
The mechanism of action of biguanides is not fully understood, and many mechanisms have been proposed for metformin. Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. Therefore, they are effective in Type 2 diabetics; and in Type 1 diabetes when used in conjunction with insulin therapy. Mainly used in Type II diabetes, metformin is considered to increase insulin sensitivity in vivo, resulting in reduced plasma glucose concentrations, increased glucose uptake, and decreased gluconeogenesis. However, in hyperinsulinemia, biguanides can lower fasting levels of insulin in plasma. Their therapeutic uses derive from their tendency to reduce gluconeogenesis in the liver, and, as a result, reduce the level of glucose in the blood. Biguanides also tend to make the cells of the body more willing to absorb glucose already present in the bloodstream, and there again reducing the level of glucose in the plasma. Biguanides have been shown to interact with copper, specifically in mitochondria, where they interfere with cell metabolism by chelating Copper in its 2+ oxidation state (Cu(II)).
=== Industrial and chemical === Technetium-99 decays almost entirely by beta decay, emitting beta particles with consistent low energies and no accompanying gamma rays. Moreover, its long half-life means that this emission decreases very slowly with time. It can also be extracted to a high chemical and isotopic purity from radioactive waste. For these reasons, it is a U.S. National Institute of Standards and Technology (NIST) standard beta emitter, and is used for equipment calibration. Technetium-99 has also been proposed for optoelectronic devices and nanoscale nuclear batteries. Like rhenium and palladium, technetium can serve as a catalyst. In processes such as the dehydrogenation of isopropyl alcohol, it is a far more effective catalyst than either rhenium or palladium. However, its radioactivity is a major problem in safe catalytic applications. When steel is immersed in water, adding a small concentration (55 ppm) of potassium pertechnetate(VII) to the water protects the steel from corrosion, even if the temperature is raised to 250 °C (523 K). For this reason, pertechnetate has been used as an anodic corrosion inhibitor for steel, although technetium's radioactivity poses problems that limit this application to self-contained systems. While (for example) CrO2−4 can also inhibit corrosion, it requires a concentration ten times as high. In one experiment, a specimen of carbon steel was kept in an aqueous solution of pertechnetate for 20 years and was still uncorroded.
The Georgia Train and Equip Program (GTEP) was an American-sponsored 18-month, $64-million program aimed at increasing the capabilities of the Georgian armed forces by training and equipping four 600-man battalions with light weapons, vehicles and communications. The program enabled the US to expedite funding for the Georgian military for Operation Enduring Freedom. On 27 February 2002, the US media reported that the U.S. would send approximately two hundred United States Army Special Forces soldiers to Georgia to train Georgian troops. The program implemented President Bush's decision to respond to the Government of Georgia's request for assistance to enhance its counter-terrorism capabilities and addressed the situation in the Pankisi Gorge. The program was planned to be a 20-month long, $64 million effort. The move drew protests from many Russians. On 1 March 2002, in response to the domestic outcry, Russian president Vladimir Putin met with Georgian president Eduard Shevardnadze in Kazakhstan and pledged his support for the American military initiative. The program began in May 2002 when American special forces soldiers of the 10th Special Forces Group began training select units of the Georgian Armed Forces, including the 12th Commando Light Infantry Battalion, the 16th Mountain-Infantry Battalion, the 13th "Shavnabada" Light Infantry Battalion, the 11th Light Infantry Battalion, a mechanized company, and small numbers of Interior Ministry troops and border guards.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.